Data released by Sheba Medical Center, Tel Hashomer, on Friday showed that coronavirus infections were reduced by 75% after the first dose of the Pfizer coronavirus vaccine.
The data, published in the peer-reviewed medical journal Lancet, focus on a study of about 9,000 Sheba health professionals, about 7,000 of whom received their first dose in January. Sheba’s team found a 75% reduction in all infections and an 85% reduction in symptomatic infections between 15-28 days after vaccination.
According to the teacher. Gili Regev-Yochay, director of the hospital’s Infectious Diseases Epidemiology Unit, only 170 people were infected during the two-week period. Of those who contracted the virus, 99 had symptoms. Eighty-nine of the patients were not vaccinated.
“In real life, the data looks at least as good as in clinical trials,” said Regev-Yochay. “The first dose is even more effective than we thought.”
“This is the first study evaluating the efficacy of a single dose of vaccine in real life conditions and shows early efficacy, even before the second dose is administered,” said Prof. Eyal Leshem, director of Sheba’s travel and tropical medicine department.
Several Israeli health funds and researchers have revealed preliminary data from the country’s vaccination campaign. This is the first study published in a peer-reviewed journal.
Regev-Yochay said that additional reports are in progress.
cnxps.cmd.push (function () {cnxps ({playerId: ’36af7c51-0caf-4741-9824-2c941fc6c17b’}). render (‘4c4d856e0e6f4e3d808bbc1715e132f6’);});
if (window.location.pathname.indexOf (“656089”)! = -1) {console.log (“hedva connatix”); document.getElementsByClassName (“divConnatix”)[0].style.display = “none”;}